Table 1.
Demographic and clinical characteristics of 77 individuals identified in VAERS without reported platelet disorders with suspected de novo ITP following SARS-CoV-2 immunization
| Characteristic | Mean ± SD, median [IQR], or n (%) | No available for analysis | |
|---|---|---|---|
| Age | 63 ± 19.7 | 76 | |
| Gender | |||
| ≤50 years old | Men | 3 (15) | 20 |
| Women | 17 (85) | ||
| >50 years old | Men | 28 (50) | 56 |
| Women | 28 (50) | ||
| Vaccine type | Moderna | 37 (48) | 77 |
| Pfizer-BioNTech | 40 (52) | ||
| No. of doses received prior to presentation | 1 2 |
51 (77.3) 15 (22.7) |
66 |
| Days to symptom onset | 8 [3.2-13] Range 0-38 |
74 | |
| Symptoms at presentation* | Mucocutaneous bleeding | 42 (73.7) | 57 |
| Genitourinary bleeding | 6 (10.5) | ||
| Gastrointestinal bleeding | 5 (6.9) | ||
| Central nervous system bleeding | 1 (1.8) | ||
| Bleeding reported but not specified | 2 (3.5) | ||
| No bleeding reported | 6 (10.5) | ||
| Platelet count at presentation | 3 [1-9] Range 0-47 |
73 | |
| ≤10 × 109/L | 58 (79.4) | ||
| History of autoimmune disease other than ITP | Any autoimmune disease | 22 (31.9) | 69 |
| Hypothyroidism† | 13 (18.8) | ||
| Rheumatologic | 4 (5.8) | ||
| Dermatologic | 2 (2.9) | ||
| Gastrointestinal | 1 (1.4) | ||
| Antiphospholipid syndrome‡ | 1 (1.4) | ||
| Multiple sclerosis | 1 (1.4) | ||
| Treatment | Any combination of steroids, IVIG, and platelet transfusion | 21 (44.7) | 46 |
| Steroids only | 16 (34) | ||
| Platelet transfusion only | 3 (8.5) | ||
| IVIG only | 1 (2.1) | ||
| TPO-RA, IVIG, +/− platelet transfusion, steroid | 3 (6.4) | ||
| Rituximab, steroids, IVIG, platelet transfusion | 1 (2.1) | ||
| Vincristine, IVIG, rituximab, TPO-RA, +/− platelet transfusion, steroid | 1 (2.1) | ||
| Response to therapy | Yes | 26 (92.9) | 28 |
| No | 2 (7.1) | ||
| Best known response | 30-50 × 109/L | 3 (11.5) | 26 |
| 50-100 × 109/L | 7 (26.9) | ||
| 100-150 × 109/L | 3 (11.5) | ||
| Normalization§ | 6 (23.1) | ||
| Improvementǁ | 7 (26.9) | ||
| Time to platelet count >30 × 109 cells/L | <3 d of treatment | 9 (81.8) | 11 |
*
More than 1 site of bleeding reported in some cases, excludes 1 patient with CNS bleeding whose thrombocytopenia resolved with platelet transfusion only and the index patient who did not present with but later developed CNS bleeding.
†
Includes 1 person with “antithyroglobulin antibody.”
‡
Antiphospholipid syndrome in the same patient with other rheumatologic conditions.
§
Platelet count ≥150 x109/L or described as “platelets normalized.”
ǁ
No platelet count provided but described as “improved” or “resolved.”